Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 1/2 1Phase 1 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1Breast 1

Conditions

Breast Neoplasms 5Prostatic Neoplasms 3Squamous Cell Carcinoma of Head and Neck 1Salivary Gland Neoplasms 1Neoplasms 1Head and Neck Neoplasms 1Gliosarcoma 1Glioblastoma 1Fallopian Tube Neoplasms 1Carcinoma, Ovarian Epithelial 1Breast Neoplasms, Male 1Brain Neoplasms 1Astrocytoma 1

Interventions

Carboplatin 16Paclitaxel 9Cyclophosphamide 8liposomal doxorubicin 6Peripheral Blood Stem Cell Transplantation 6Topotecan 5Filgrastim 5pembrolizumab 4Docetaxel 4oregovomab 3veliparib 2sacituzumab govitecan 2epacadostat 2avelumab 2Thiotepa 2Taxes 2STA 9090 2Nivolumab 2Erlotinib Hydrochloride 2Drug Therapy 2Cisplatin 2Amifostine 2talazoparib 1ribociclib 1relacorilant 1ralimetinib 1poly ICLC 1phenoxodiol 1peginterferon alfa-2b 1pegfilgrastim 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Carcinoma, Ovarian Epithelial × ixabepilone × Clear all
NCT00182767 2016-03-10

Ixabepilone and Liposomal Doxorubicin in Advanced Ovarian Cancer

National Cancer Institute (NCI)

Phase 1/2 Completed
45 enrolled 8 charts
BreastGynecologic

Carcinoma, Ovarian Epithelial, Breast Neoplasms, Fallopian Tube Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡